July 8, 2010Cardiovascular Therapeutics
The Antianginal Agent Ranolazine is a Potent Antiarrhythmic Agent that Reduces Ventricular Arrhythmias: Through a Mechanism Favoring Inhibition of Late Sodium Channel
Why the study?
Does low-dose ranolazine reduce ischemia/reperfusion-induced ventricular arrhythmias in anesthetized rats?
Population
20 anesthetized rats subjected to 5 min of proximal left coronary artery occlusion followed by 5 min of…
Comparison
Low dose ranolazine vs Vehicle control
Design
Preclinical, Rats were randomized to vehicle control versus low dose R
Follow-up
5 minutes of reperfusion
Authors
Discussion
Loading...
Member takes
Implication
May warrant preclinical follow-up but not clinical use; leaves open translation of ranolazine's antiarrhythmic effect to humans.
Structured PICO
Does low-dose ranolazine reduce ischemia/reperfusion-induced ventricular arrhythmias in anesthetized rats?
P
Population
20 anesthetized rats subjected to 5 min of proximal left coronary artery occlusion followed by 5 min of reperfusion
I
Intervention
Low dose ranolazine (3.33 mg/kg i.v. bolus plus 3.2 mg/kg/h started 20 min prior to occlusion, yielding a concentration of 4 μM)
C
Comparator
Vehicle control
O
Outcome
Reperfusion-induced arrhythmias quantitated by electrocardiographic monitoring (including any arrhythmias, ventricular tachycardia, and ventricular premature beats)surrogate
Low-dose ranolazine significantly reduces ischemia/reperfusion-induced ventricular arrhythmias in a rat model, consistent with a mechanism involving inhibition of the late sodium current.
Cite This Study
Kloner et al. (2010) studied this question.